Advertisement
Interested parties may also access a live webcast of the presentation byvisiting the "Events Calendar" page under the "Investors/Press" tab on Kosan'swebsite at http://www.kosan.com. A recorded replay of the presentations willbe available for two weeks.
Advertisement
About Kosan
Kosan Biosciences is a biotechnology company advancing two new classes ofanticancer agents through clinical development -- Hsp90 (heat shock protein90) inhibitors and epothilones. Kosan is leveraging its proprietary discoveryplatform to generate a pipeline of potentially significant product candidates,primarily in the area of oncology.
Hsp90 inhibitors have a novel mechanism of action targeting multiplepathways involved in cancer cell growth and survival. Tanespimycin (KOS-953)is being tested in combination with bortezomib in patients with multiplemyeloma in a registration program called TIME. Tanespimycin is also beingstudied in HER2-positive metastatic breast cancer in combination withHerceptin, and as monotherapy in metastatic melanoma. Intravenous and oralformulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin(KOS-1022), are being evaluated in Phase 1 clinical trials in hematologicalcancers and in HER2-positive metastatic breast cancer.
Epothilones inhibit cell division with a mechanism of action similar totaxanes, one of the most successful classes of anti-tumor agents. KOS-1584 isin Phase 1 clinical trials in patients with solid tumors.
Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in aPhase 1 trial in gastroesophageal reflux disease (GERD).
For additional information on Kosan Biosciences, please visit Kosan'swebsite at http://www.kosan.com.
SOURCE Kosan Biosciences Incorporated
